Nutritional Counseling

Consultation and Outreach with a Registered Dietitian

Carbohydrate tolerance and the severity of gastrointestinal symptoms are highly variable among patients diagnosed with Congenital Sucrase-Isomaltase Deficiency (CSID). For this reason, dietary restrictions should be customized for each patient. To ensure a restriction diet meets each individual’s nutritional needs, the patient who still has symptoms while on Sucraid therapy should be referred to a registered dietitian specializing in gastroenterology for diet assessment, education and follow up.

A restriction or elimination diet may be beneficial if a patient still has symptoms after initiating Sucraid therapy.

Eliminating dietary sources of both sucrose and starch may be recommended for only one to two weeks, as such a diet may not be nutritionally complete. After two weeks, sucrose- and starch-containing foods may be systematically added back to the diet while monitoring for gastrointestinal (GI) symptoms.

Getting Started with a Low-Sucrose, Low-Starch Diet

Infant Dietary Guide

Infant Dietary Guide for Individuals Treated with Sucraid

Child Dietary Guide

Child Dietary Guide for Individuals Treated with Sucraid

Adult Dietary Guide

Adult Dietary Guide for Individuals Treated with Sucraid

Dietary Menu

Dietary Menu for Individuals Treated with Sucraid

For More Information and Resources

Call the SucraidASSIST™ Registered Dietitian

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

  • Sucraid may cause a serious allergic reaction. Patients should stop taking Sucraid and get emergency help immediately if any of the following side effects occur: difficulty breathing, wheezing, or swelling of the face. Care should be taken when administering initial doses of Sucraid to observe any signs of acute hypersensitivity reaction.
  • Do not use Sucraid (sacrosidase) Oral Solution with patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol).
  • Although Sucraid provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase.
  • Adverse reactions as a result of taking Sucraid may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
  • Before prescribing Sucraid to diabetic patients, the physician should consider that Sucraid will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose.
  • The effects of Sucraid have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
  • DO NOT HEAT SOLUTIONS CONTAINING SUCRAID. Do not put Sucraid in warm or hot fluids. Do not reconstitute or consume Sucraid with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid. Half of the reconstituted Sucraid should be taken at the beginning of the meal or snack and the other half during the meal or snack.
  • Sucraid should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light.


Sucraid®(sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of Congenital Sucrase-Isomaltase Deficiency (CSID).